FIELD: biotechnology.
SUBSTANCE: described is a group of inventions comprising a nucleic acid for inhibiting expression of LPA in a cell, a conjugate for inhibiting expression of LPA in a cell (embodiments), composition for preventing, or treating, or reducing the risk of developing cardiovascular disease and use of nucleic acid, or a conjugate, or a composition for preventing, or treating, or reducing the risk of developing a cardiovascular disease. In one embodiment, the nucleic acid comprises at least one duplex region, which contains at least part of first chain and at least part of second chain, which is at least partially complementary to said first chain, wherein said first strand is at least partially complementary to at least a portion of the RNA transcribed from the LPA gene.
EFFECT: invention extends the range of agents for inhibiting expression of LPA in a cell.
26 cl, 40 dwg, 15 tbl, 15 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS FOR TREATMENT OF HEPATITIS B INFECTION | 2018 |
|
RU2780021C2 |
| NUCLEIC ACIDS FOR INHIBITION OF TARGET GENE EXPRESSION CONTAINING PHOSPHODITHIOATE BONDS | 2018 |
|
RU2812806C2 |
| HSP47 EXPRESSION MODULATION | 2010 |
|
RU2575056C2 |
| LOW-MOLECULAR CONJUGATES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | 2011 |
|
RU2582235C2 |
| LNA OLIGONUCLEOTIDE CARBOHYDRATE CONJUGATES | 2014 |
|
RU2649367C2 |
| COMPOSITIONS AND METHODS FOR MODULATING HBV AND TTR EXPRESSION | 2014 |
|
RU2670614C9 |
| COMPOSITIONS AND METHODS | 2014 |
|
RU2686080C2 |
| COMPOSITIONS AND METHODS FOR MODULATING EXPRESSION OF APOLIPOPROTEIN (A) | 2014 |
|
RU2824214C1 |
| COMPOSITIONS AND METHODS OF MODULATING APOLIPOPROTEIN C-III EXPRESSION | 2014 |
|
RU2650510C2 |
| COMPOSITIONS AND METHODS FOR MODULATION OF HBV AND TTR EXPRESSION | 2014 |
|
RU2782034C2 |
